- Home
- SHOT vs LEXX Comparison
SHOT vs LEXX Comparison
Compare SHOT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- LEXX
- Stock Information
- Founded
- SHOT 2018
- LEXX 2004
- Country
- SHOT United States
- LEXX Canada
- Employees
- SHOT N/A
- LEXX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- LEXX Health Care
- Exchange
- SHOT Nasdaq
- LEXX Nasdaq
- Market Cap
- SHOT 44.2M
- LEXX 38.9M
- IPO Year
- SHOT 2020
- LEXX N/A
- Fundamental
- Price
- SHOT $0.72
- LEXX $2.23
- Analyst Decision
- SHOT
- LEXX Strong Buy
- Analyst Count
- SHOT 0
- LEXX 2
- Target Price
- SHOT N/A
- LEXX $11.00
- AVG Volume (30 Days)
- SHOT 887.0K
- LEXX 202.7K
- Earning Date
- SHOT 11-14-2024
- LEXX 01-10-2025
- Dividend Yield
- SHOT N/A
- LEXX N/A
- EPS Growth
- SHOT N/A
- LEXX N/A
- EPS
- SHOT N/A
- LEXX N/A
- Revenue
- SHOT $652,495.00
- LEXX $464,278.00
- Revenue This Year
- SHOT N/A
- LEXX $20.39
- Revenue Next Year
- SHOT N/A
- LEXX $113.25
- P/E Ratio
- SHOT N/A
- LEXX N/A
- Revenue Growth
- SHOT 68.01
- LEXX 105.24
- 52 Week Low
- SHOT $0.55
- LEXX $1.20
- 52 Week High
- SHOT $4.40
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- SHOT 33.82
- LEXX 47.23
- Support Level
- SHOT $0.89
- LEXX $2.00
- Resistance Level
- SHOT $1.03
- LEXX $2.54
- Average True Range (ATR)
- SHOT 0.09
- LEXX 0.24
- MACD
- SHOT -0.02
- LEXX -0.00
- Stochastic Oscillator
- SHOT 13.58
- LEXX 27.06
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.